Limits...
Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn's Disease with Infliximab Therapy.

Kim MJ, Lee WY, Choe YH - Gut Liver (2015)

Bottom Line: A significant difference in HBD-2 mRNA expression was found in colonic mucosa between CD patients before infliximab therapy and the healthy controls (p=0.013).Our study suggests that both the adaptive and innate immune systems are closely linked to each other in CD pathogenesis.And the results of our study indicate that it could be a useful therapeutic tool, where restoration of TIM-3, HBD-2 and the function of Tregs may repair the dysfunctional immunoregulation in CD.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.

ABSTRACT

Background/aims: This study investigated the expression of T cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3), human β-defensin (HBD)-2, forkhead box protein 3 (FOXP3), and the frequency of CD4(+) CD25(+) FOXP3(+) regulatory T cells (Tregs) in children with Crohn's disease (CD) during infliximab therapy.

Methods: We enrolled 20 CD patients who received infliximab treatment for 1 year. Peripheral blood and colonic mucosal specimens were collected from all CD patients and from healthy control individuals.

Results: A significant difference in TIM-3 mRNA expression was evident in peripheral blood mononuclear cells and colonic mucosa between CD patients before infliximab therapy and the healthy controls (p<0.001 and p=0.005, respectively). A significant difference in HBD-2 mRNA expression was found in colonic mucosa between CD patients before infliximab therapy and the healthy controls (p=0.013). In the active phase of CD, at baseline, the median percentage of T cells that were CD25(+) FOXP3(+) was 1.5% (range, 0.32% to 3.49%), which increased after inflixmab treatment for 1 year to 2.2% (range, 0.54% to 5.02%) (p=0.008).

Conclusions: Our study suggests that both the adaptive and innate immune systems are closely linked to each other in CD pathogenesis. And the results of our study indicate that it could be a useful therapeutic tool, where restoration of TIM-3, HBD-2 and the function of Tregs may repair the dysfunctional immunoregulation in CD.

Show MeSH

Related in: MedlinePlus

Expression of the T cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) and forkhead box protein 3 (FOXP3) proteins in the colonic mucosa of patients with Crohn’s disease (CD) before and after infliximab therapy and normal controls. The immunoreactive TIM-3 protein in normal controls (A) was compared with that in CD patients before (B) and after (C) infliximab therapy by immunohistochemical analysis using anti-TIM-3 antibodies as described in the Materials and Methods section. The immunoreactive FOXP3 protein in CD patients before (E) and after (F) infliximab therapy was compared with that in normal controls (D) by immunohistochemical analysis using anti-FOXP3 antibodies as described in the Materials and Methods section (×400).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4413971&req=5

f8-gnl-09-370: Expression of the T cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) and forkhead box protein 3 (FOXP3) proteins in the colonic mucosa of patients with Crohn’s disease (CD) before and after infliximab therapy and normal controls. The immunoreactive TIM-3 protein in normal controls (A) was compared with that in CD patients before (B) and after (C) infliximab therapy by immunohistochemical analysis using anti-TIM-3 antibodies as described in the Materials and Methods section. The immunoreactive FOXP3 protein in CD patients before (E) and after (F) infliximab therapy was compared with that in normal controls (D) by immunohistochemical analysis using anti-FOXP3 antibodies as described in the Materials and Methods section (×400).

Mentions: Colonic mucosa from CD patients before and after infliximab therapy and healthy controls were stained by immunohistochemical methods. The expression of TIM-3 and FOXP3 was detected histologically in the colonic mucosa of CD patients, and was decreased according to infliximab treatment. In contrast, no staining was observed in the colonic mucosa of healthy controls (Fig. 8).


Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn's Disease with Infliximab Therapy.

Kim MJ, Lee WY, Choe YH - Gut Liver (2015)

Expression of the T cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) and forkhead box protein 3 (FOXP3) proteins in the colonic mucosa of patients with Crohn’s disease (CD) before and after infliximab therapy and normal controls. The immunoreactive TIM-3 protein in normal controls (A) was compared with that in CD patients before (B) and after (C) infliximab therapy by immunohistochemical analysis using anti-TIM-3 antibodies as described in the Materials and Methods section. The immunoreactive FOXP3 protein in CD patients before (E) and after (F) infliximab therapy was compared with that in normal controls (D) by immunohistochemical analysis using anti-FOXP3 antibodies as described in the Materials and Methods section (×400).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4413971&req=5

f8-gnl-09-370: Expression of the T cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) and forkhead box protein 3 (FOXP3) proteins in the colonic mucosa of patients with Crohn’s disease (CD) before and after infliximab therapy and normal controls. The immunoreactive TIM-3 protein in normal controls (A) was compared with that in CD patients before (B) and after (C) infliximab therapy by immunohistochemical analysis using anti-TIM-3 antibodies as described in the Materials and Methods section. The immunoreactive FOXP3 protein in CD patients before (E) and after (F) infliximab therapy was compared with that in normal controls (D) by immunohistochemical analysis using anti-FOXP3 antibodies as described in the Materials and Methods section (×400).
Mentions: Colonic mucosa from CD patients before and after infliximab therapy and healthy controls were stained by immunohistochemical methods. The expression of TIM-3 and FOXP3 was detected histologically in the colonic mucosa of CD patients, and was decreased according to infliximab treatment. In contrast, no staining was observed in the colonic mucosa of healthy controls (Fig. 8).

Bottom Line: A significant difference in HBD-2 mRNA expression was found in colonic mucosa between CD patients before infliximab therapy and the healthy controls (p=0.013).Our study suggests that both the adaptive and innate immune systems are closely linked to each other in CD pathogenesis.And the results of our study indicate that it could be a useful therapeutic tool, where restoration of TIM-3, HBD-2 and the function of Tregs may repair the dysfunctional immunoregulation in CD.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.

ABSTRACT

Background/aims: This study investigated the expression of T cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3), human β-defensin (HBD)-2, forkhead box protein 3 (FOXP3), and the frequency of CD4(+) CD25(+) FOXP3(+) regulatory T cells (Tregs) in children with Crohn's disease (CD) during infliximab therapy.

Methods: We enrolled 20 CD patients who received infliximab treatment for 1 year. Peripheral blood and colonic mucosal specimens were collected from all CD patients and from healthy control individuals.

Results: A significant difference in TIM-3 mRNA expression was evident in peripheral blood mononuclear cells and colonic mucosa between CD patients before infliximab therapy and the healthy controls (p<0.001 and p=0.005, respectively). A significant difference in HBD-2 mRNA expression was found in colonic mucosa between CD patients before infliximab therapy and the healthy controls (p=0.013). In the active phase of CD, at baseline, the median percentage of T cells that were CD25(+) FOXP3(+) was 1.5% (range, 0.32% to 3.49%), which increased after inflixmab treatment for 1 year to 2.2% (range, 0.54% to 5.02%) (p=0.008).

Conclusions: Our study suggests that both the adaptive and innate immune systems are closely linked to each other in CD pathogenesis. And the results of our study indicate that it could be a useful therapeutic tool, where restoration of TIM-3, HBD-2 and the function of Tregs may repair the dysfunctional immunoregulation in CD.

Show MeSH
Related in: MedlinePlus